Yangshengtang Co., Ltd
2 clinical trials · Sponsor
◉ Watch Yangshengtang Co., Ltd
| Record | Firm | Date |
|---|---|---|
| A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection (NCT06159062) | Yangshengtang Co., Ltd | 2024-06-03 |
| Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects (NCT05310487) | Yangshengtang Co., Ltd | 2022-09-30 |
Track Yangshengtang Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.